Health ❯ Pharmaceuticals

Clinical Trials

Drug Development Drug Safety Weight Loss Drugs Regulatory Affairs Regulatory Compliance Cancer Treatment Weight Loss Regulatory Approval Safety Protocols Obesity Treatments

Single Psilocybin Dose Rewires Brain-Wide Circuits in Mice, Cell Study Finds

A rabies-based tracer mapped reduced cortical feedback alongside stronger sensory-to-subcortical links in a preclinical model relevant to depression.

aTyr Investors Face Dec. 8 Deadline in Securities Suits Over Efzofitimod Trial Failure

aTyr Investors Face Dec. 8 Deadline as Rival Lawsuits Over Failed Sarcoidosis Trial Intensify

Skye Bioscience Hit With Securities Class Action Over Nimacimab Disclosures as Firms Court Lead Plaintiff

Bayer Stroke Drug Asundexian Hits Phase III Goals, Shares Jump

Agios’ Sickle Cell Pill Lifts Hemoglobin but Misses Pain-Crisis Goal in Phase 3

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Yale Study Finds Only 24% of Medicines Tested Reach Trial-Host Countries Within Five Years

Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action

Savara Investors Pressed to Meet Class-Action Deadlines Over Alleged MOLBREEVI BLA Deficiencies

New aTyr Class Action Expands Investor Window After EFZO-FIT Failure

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

Law Firms Urge Jasper Therapeutics Investors to Seek Lead‑Plaintiff Role Before Nov. 18 Deadline

FDA Clears Monthly Uzedy Injection for Maintenance Treatment of Bipolar I Disorder

Savara Investors Face Nov. 7 Lead‑Plaintiff Deadline in Securities Suit Over FDA Refusal‑to‑File

Metsera’s Obesity Drug Posts 14% Placebo-Adjusted Weight Loss, Bolstering Pfizer Buyout Case

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

CSL Secures VarmX Acquisition Option, Funding Phase 3 of Factor Xa Reversal Drug

SYNT-101 Shows Promise in Early Human Trials as a Non-Invasive Obesity Treatment

Merck Secures $2 Billion Deal for Experimental Oral Weight Loss Drug from Hansoh Pharma